Doctors condemn big pharma’s move to dispense GLP-1s to your door

• Eli Lilly has launched LillyDirect, an online platform that allows patients to have GLP-1 medications, such as Mounjaro, delivered directly to their homes through third-party pharmacists.
• The pharmaceutical company claims the service offers competitive pricing and convenience while maintaining the requirement for an independent doctor’s prescription.
• Medical and pharmacy groups have condemned the model, arguing that bypassing face-to-face clinical interactions poses significant risks to patient safety and undermines continuity of care.

A multi-billion-dollar global pharmaceutical giant’s decision to bypass traditional pharmacies and ship GLP-1 medications directly to patients’ homes has sparked a wave of criticism from medical professionals. Doctors and pharmacists warn that this direct-to-consumer approach could compromise patient safety in exchange for convenience.

Eli Lilly recently launched LillyDirect, a digital platform designed to dispense specific medications, including tirzepatide. Marketed under the brand name Mounjaro, this injectable GLP-1 agonist is a potent treatment widely used for type 2 diabetes and obesity.

The new model allows patients to upload an electronic prescription from their doctor to the LillyDirect website. The script is then forwarded to a third-party online pharmacist for dispensing before being delivered to the patient’s doorstep. Eli Lilly claims the platform simplifies the process, offering patients competitive pricing without the need to shop around, while emphasizing that the service does not replace the need for an independent physician to prescribe the drug.

However, the medical community is raising red flags. Dr. Michael Wright, president of the Royal Australian College of GPs (RACGP), cautioned that GLP-1 agonists are powerful medications with significant potential side effects. He argues that these treatments require rigorous oversight and a high level of “continuity of care” that an automated online system cannot provide.

Dr. Wright noted that removing the local pharmacist strips away a vital layer of protection for the patient. He expressed particular concern for those already using telehealth providers to obtain prescriptions, as the combination of online prescribing and online dispensing means the medication could be handled by people who lack access to the patient’s full medical history.

The Pharmacy Guild of Australia and the Pharmaceutical Society of Australia have echoed these sentiments, labeling the direct-delivery model “clinically inferior.” They argue that the shift reduces essential face-to-face interactions, which are often the only opportunities for healthcare professionals to identify and address potential complications before they become serious.

... read the full article here